Literature DB >> 25846343

Reversal of warfarin anticoagulation for urgent surgical procedures.

Rachel Curtis1, Alexandra Schweitzer, Janet van Vlymen.   

Abstract

PURPOSE: Patients treated with warfarin for therapeutic anticoagulation present a challenge for the perioperative management of urgent and emergent surgery. Anticoagulation must be reversed prior to most surgical procedures to prevent intraoperative bleeding. The purpose of this module is to review the options for urgent reversal of warfarin anticoagulation and the indications for each reversal agent. Selection of the appropriate agent is important to reduce unnecessary complications of treatment and to achieve optimal reversal of anticoagulation. PRINCIPAL
FINDINGS: When urgent surgery is required for patients taking warfarin, intravenous vitamin K1 should be used for procedures that can be delayed for six to 12 hr. Vitamin K1 results in the activation of existing clotting factors rather than requiring the synthesis of new proteins, which allows for its relatively rapid onset of action. Intravenous vitamin K1 acts more quickly than oral administration, with reversal of anticoagulation occurring within six to 12 hr vs 18-24 hr, respectively. If surgery cannot be delayed, prothrombin complex concentrates (PCCs) should be given, and intravenous vitamin K1 should be infused concurrently to ensure sustained reversal of anticoagulation. The duration of action of both PCCs and plasma is six hours due to the short half-life of factor VII. Prothrombin complex concentrates contain small amounts of heparin and are contraindicated in patients with heparin-induced thrombocytopenia. Plasma should be used only if PCCs are unavailable or are contraindicated.
CONCLUSION: Reversal of warfarin anticoagulation can be achieved in a safe and timely manner when the appropriate agent is selected and administered correctly.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25846343     DOI: 10.1007/s12630-015-0366-3

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  7 in total

1.  Direct oral anticoagulants (DOACs) and neck of femur fractures: Standardising the perioperative management and time to surgery.

Authors:  Rohi Shah; Nomaan Sheikh; Jitendra Mangwani; Nicolette Morgan; Hamidreza Khairandish
Journal:  J Clin Orthop Trauma       Date:  2020-08-23

2.  Partial warfarin reversal prior to hip fracture surgical intervention in geriatric trauma patients effects on blood loss and transfusions.

Authors:  Richard Meinig; David Cornutt; Stephanie Jarvis; Kristin Salottolo; Michael Kelly; Paul Harrison; Michelle Nentwig; Steven Morgan; Nnamdi Nwafo; Patrick McNair; Rahul Banerjee; Bradley Woods; David Bar-Or
Journal:  J Clin Orthop Trauma       Date:  2020-09-28

3.  Is anticoagulation reversal necessary prior to surgical treatment of geriatric hip fractures?

Authors:  Rick Meinig; Stephanie Jarvis; Alessandro Orlando; Nnamdi Nwafo; Rahul Banerjee; Patrick McNair; Bradley Woods; Paul Harrison; Michelle Nentwig; Michael Kelly; Wade Smith; David Bar-Or
Journal:  J Clin Orthop Trauma       Date:  2019-10-15

Review 4.  Application of fresh frozen plasma transfusion in the management of excessive warfarin-associated anticoagulation.

Authors:  Yuanyuan Luo; Chunya Ma; Yang Yu
Journal:  Blood Sci       Date:  2022-05-17

Review 5.  Cardiac tachyarrhythmias and anaesthesia: General principles and focus on atrial fibrillation.

Authors:  Satyen Parida; Chitra Rajeswari Thangaswamy
Journal:  Indian J Anaesth       Date:  2017-09

6.  Management of anticoagulation in hip fractures: A pragmatic approach.

Authors:  Rafik Yassa; Mahdi Yacine Khalfaoui; Ihab Hujazi; Hannah Sevenoaks; Paul Dunkow
Journal:  EFORT Open Rev       Date:  2017-09-21

7.  Is intravenous thrombolysis safe for acute ischemic stroke patients taking warfarin with INR 1.9?: A case report.

Authors:  Zhaokun Li; Jing Su; Shanshan Zhang; Hongcai Du; Yufeng Tang; Jingfeng Duan; Zhonglun Chen
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.